

Cervical Cancer

A Study to Evaluate Safety and Effectiveness of Bevacizumab in Combination With Paclitaxel and Cisplatin/Carboplatin or Toptecan in Participants With Advanced Cervical Cancer

Trial Status
Completed

Trial Runs In
1 Countries

Trial Identifier
NCT03071848 ML39360

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This study will evaluate the safety of bevacizumab (Avastin®) combined with standard chemotherapy in participant with advanced cervical cancer, with special focus on the incidence of gastrointestinal (GI) and genitourinary (GU) fistulas and GI perforations in the common practice setting.

Hoffmann-La Roche
Sponsor

Phase

NCT03071848 ML39360
Trial Identifiers

Eligibility Criteria:

Gender
Female

Age
≥ 18 Years

Healthy Volunteers
No